NCT00661765View on ClinicalTrials.gov

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Smoking Cessation
Interventions
DRUG

varenicline tartrate

Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation

DRUG

varenicline free base

A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.

Trial Locations (1)

58104

Pfizer Investigational Site, Fargo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00661765 - A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers. | Biotech Hunter | Biotech Hunter